Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 3 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 147Melanoma 122Breast Neoplasms 98Squamous Cell Carcinoma of Head and Neck 96Triple Negative Breast Neoplasms 85Lung Neoplasms 64Neoplasm Metastasis 53Carcinoma, Renal Cell 49Neoplasms 46Head and Neck Neoplasms 46Colorectal Neoplasms 41Ovarian Neoplasms 38Carcinoma, Transitional Cell 37Carcinoma, Hepatocellular 36Pancreatic Neoplasms 35Urinary Bladder Neoplasms 34Recurrence 33Stomach Neoplasms 32Glioblastoma 30Brain Neoplasms 28Sarcoma 26Endometrial Neoplasms 25Prostatic Neoplasms 23Hodgkin Disease 22Uterine Cervical Neoplasms 19Fallopian Tube Neoplasms 19Carcinoma, Squamous Cell 19Esophageal Squamous Cell Carcinoma 17Adenocarcinoma 17Multiple Myeloma 16

Interventions

Carboplatin 5pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × pembrolizumab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
17 enrolled

Pathologic Complete Response

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04435197 2024-07-03

PALACE-2

Ruijin Hospital

Phase 2 Completed
143 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡